Sun Pharmaceutical Industries Ltd (SUNPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 948699, "name": "Sun Pharma.Inds.", "stock_name": "Sun Pharma.Inds.", "full_name": "Sun Pharmaceutical Industries Ltd", "name_url": "stocks-analysis/sun-pharmainds", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,840.90", "chg": -3.7, "chgp": "-0.2%", "dir": -1, "prev_price": "1,844.60", "mcapval": "441,693.57 Cr", "mcap": "Large Cap", "scripcode": 524715, "symbol": "SUNPHARMA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE044A01036", "curr_date": "May 25", "curr_time": "", "bse_nse_vol": "16.2 lacs", "exc_status": "Active", "traded_date": "May 25, 2026", "traded_date_str": "2026 05 25", "score": "", "scoreText": "", "Live": 0, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "13,543 Call Contracts at Rs 1,860 Strike on Sun Pharmaceutical Industries Ltd Signal Near-Term Upside Interest", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-surge-in-call-option-activity-ahead-of-expiry-4010675", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SunPharmaceutic_most_active_stocks_calls_4010675.png", "date": "2026-05-25 11:00:13", "description": "On 25 May 2026, Sun Pharmaceutical Industries Ltd witnessed significant call option activity with 13,543 contracts traded at the Rs 1,860 strike price. The stock closed at Rs 1,845.20, just below this strike, indicating a strong directional interest in the near term as expiry approaches on 26 May 2026." }, { "title": "Rs 1,800 Puts — 2.4% Below Current Price — Draw 7,274 Contracts on Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-ahead-of-expiry-4010671", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SunPharmaceutic_most_active_stocks_puts_4010671.png", "date": "2026-05-25 11:00:12", "description": "Rs 1,800 put options on Sun Pharmaceutical Industries Ltd attracted 7,274 contracts on 25 May 2026, representing significant activity just below the current stock price of Rs 1,844.50. This surge in put trading, close to expiry, invites a closer look at whether it signals bearish positioning, hedging, or put writing." }, { "title": "Sun Pharmaceutical Industries Ltd Reports Flat Quarterly Performance Amid Margin Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-reports-flat-quarterly-performance-amid-margin-pressure-4009745", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SunPharmaceutic_fintrenddot_4009745.png", "date": "2026-05-25 08:00:19", "description": "Sun Pharmaceutical Industries Ltd, a leading player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. The company’s profitability metrics have contracted, reflecting challenges in sustaining margin expansion amid a competitive and cost-sensitive environment." }, { "title": "Are Sun Pharmaceutical Industries Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-sun-pharmaceutical-industries-ltd-latest-results-good-or-bad-4008987", "imagepath": "", "date": "2026-05-23 19:24:54", "description": "Sun Pharmaceutical Industries Ltd's latest financial results for Q4 FY26 present a mixed picture of performance. The company reported net sales of ₹14,611.79 crores, reflecting a year-on-year growth of 12.76%, driven by volume growth and product launches. However, there was a sequential decline of 5.86% compared to the previous quarter, which aligns with typical seasonal patterns but was more pronounced than historical averages.\n\nNet profit for the quarter stood at ₹2,714 crores, showing a significant year-on-year increase of 26.24%. Nonetheless, this figure represented a decline of 19.44% on a sequential basis, raising concerns about the company's profitability dynamics. The operating margin also faced pressure, contracting to 27.16% from 31.99% in the previous quarter, indicating challenges related to pricing pressures and cost inflation.\n\nFor the full fiscal year FY26, Sun Pharma achieved a consolidated ..." }, { "title": "Sun Pharmaceutical Industries Ltd Declines 1.85% Despite 52-Week Highs and Elevated Derivatives Activity", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-declines-185-despite-52-week-highs-and-elevated-derivatives-activity-4008350", "imagepath": "", "date": "2026-05-23 14:05:28", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>18 May:</strong> New 52-week high at Rs.1,891.15</p>\n <p><strong>19 May:</strong> All-time high reached Rs.1,917.15; rating downgraded to Buy</p>\n <p><strong>22 May:</strong> Significant open interest surge amid mixed price action</p>\n <p><strong>22 May:</strong> Week closes at Rs.1,845.20 (-1.85%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,880.00</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,845.20</div><div class..." }, { "title": "Sun Pharma Q4 FY26: Profit Surge Masks Margin Pressure as US Challenges Persist", "link": "https://www.marketsmojo.com/news/result-analysis/sun-pharma-q4-fy26-profit-surge-masks-margin-pressure-as-us-challenges-persist-4007562", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SunPharmaceutic_quaterlyResult_4007562.png", "date": "2026-05-22 21:47:36", "description": "Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company and the fourth-largest global specialty generic firm, delivered a mixed performance in Q4 FY26 (January-March 2026), with consolidated net profit climbing 26.24% year-on-year to ₹2,714.03 crores despite a sequential decline of 19.44% from Q3 FY26. The ₹453,306-crore market capitalisation company saw its stock retreat 2.43% to ₹1,845.20 following the results announcement, as investors grappled with margin compression and sequential profit decline despite robust annual growth." }, { "title": "Sun Pharmaceutical Sees Significant Open Interest Surge Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-significant-open-interest-surge-amid-mixed-market-signals-4005518", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SunPharmaceutic_oi_spurts_by_underlying_4005518.png", "date": "2026-05-22 15:00:52", "description": "Sun Pharmaceutical Industries Ltd has witnessed a notable 12.3% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, the surge in open interest alongside volume patterns suggests evolving directional bets among traders in the pharmaceuticals sector." }, { "title": "Sun Pharmaceutical Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-notable-surge-in-derivatives-open-interest-amid-mixed-market-signals-4005412", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SunPharmaceutic_oi_spurts_by_underlying_4005412.png", "date": "2026-05-22 14:00:42", "description": "Sun Pharmaceutical Industries Ltd has witnessed a notable 10.9% increase in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite a modest decline in the stock price, this surge in open interest coupled with volume patterns suggests evolving directional bets in the large-cap pharmaceutical heavyweight." }, { "title": "P/E at 37.25 vs Industry's 34.53: What the Data Shows for Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-amidst-nifty-50-benchmark-dynamics-4004587", "imagepath": "", "date": "2026-05-22 09:21:34", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Premium Above Industry Average</strong></p>\n <p><a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> trades at a P/E of 37.25, which is approximately 7.9% higher than the Pharmaceuticals & Biotechnology sector average of 34.53. This premium suggests that investors are willing to pay more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or a perception of higher quality. However, the valuation premium also raises questions about whether the current price fully discounts risks or if it leaves limited room for upside — <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"ctx\">previously..." } ], "total": 1125, "sid": "948699", "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699" }, "announcements": [ { "details": "Sun Pharmaceutical Industries Limited has informed the Exchange regarding Intimation under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015", "source": "NSE", "caption": "Sun Pharmaceutical Industries Limited - Other General Purpose", "datetime": "09-Dec-2019" }, { "details": "Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 06, 2019, titled \"Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China\".", "source": "NSE", "caption": "Sun Pharmaceutical Industries Limited - Press Release", "datetime": "06-Nov-2019" }, { "details": "Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Please find enclosed Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018'.", "source": "NSE", "caption": "Sun Pharmaceutical Industries Limited - Updates", "datetime": "18-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>1100%</strong> dividend, ex-date: 05 Feb 26", "dt": "2026-02-05", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10", "dt": "2010-11-25", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13", "dt": "2013-07-29", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

18 May: New 52-week high at Rs.1,891.15

19 May: All-time high reached Rs.1,917.15; rating downgraded to Buy

22 May: Significant open interest surge amid mixed price action

22 May: Week closes at Rs.1,845.20 (-1.85%)

Read full news article

Sun Pharma Q4 FY26: Profit Surge Masks Margin Pressure as US Challenges Persist

2026-05-22 21:47:36

Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company and the fourth-largest global specialty generic firm, delivered a mixed performance in Q4 FY26 (January-March 2026), with consolidated net profit climbing 26.24% year-on-year to ₹2,714.03 crores despite a sequential decline of 19.44% from Q3 FY26. The ₹453,306-crore market capitalisation company saw its stock retreat 2.43% to ₹1,845.20 following the results announcement, as investors grappled with margin compression and sequential profit decline despite robust annual growth.

Read full news article

Sun Pharmaceutical Sees Significant Open Interest Surge Amid Mixed Market Signals

2026-05-22 15:00:52

Sun Pharmaceutical Industries Ltd has witnessed a notable 12.3% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, the surge in open interest alongside volume patterns suggests evolving directional bets among traders in the pharmaceuticals sector.

Read full news article

Sun Pharmaceutical Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals

2026-05-22 14:00:42

Sun Pharmaceutical Industries Ltd has witnessed a notable 10.9% increase in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite a modest decline in the stock price, this surge in open interest coupled with volume patterns suggests evolving directional bets in the large-cap pharmaceutical heavyweight.

Read full news article

P/E at 37.25 vs Industry's 34.53: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-05-22 09:21:34

Valuation Picture: Premium Above Industry Average

Sun Pharmaceutical Industries Ltd trades at a P/E of 37.25, which is approximately 7.9% higher than the Pharmaceuticals & Biotechnology sector average of 34.53. This premium suggests that investors are willing to pay more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or a perception of higher quality. However, the valuation premium also raises questions about whether the current price fully discounts risks or if it leaves limited room for upside — previously...

Read full news article

View All News